# Ten-perspective research and narration audit

Date: 27 September 2026. Ibuprofen, standard oral tablet educational prototype. Independent clinical, scientific, anatomy and translation reviews remain pending.

The questions and ordering below are editorial recommendations informed by separate role-specific searches and source readings. They are not measured search-frequency rankings or proven best explanations. Accessible official pages were read directly; retrieval limits for scientific and guideline pages are recorded below.

## Source register

- [NHS](https://www.nhs.uk/medicines/ibuprofen-for-adults/)

- [MedlinePlus](https://medlineplus.gov/druginfo/meds/a682159.html)

- [Child dosing](https://medlineplus.gov/ency/patientinstructions/000772.htm)

- [US OTC label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=733d0b21-c177-4c60-9243-2f1e7cb5854a)

- [Prescription label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b40f39e4-a37c-4039-ae37-210c1c3c6235)

- [BCEHS](https://handbook.bcehs.ca/drug-monographs/ibuprofen/)

- [FDA aspirin](https://www.fda.gov/drugs/safe-use-aspirin/information-about-taking-ibuprofen-and-aspirin-together)

- [AHRQ](https://www.ahrq.gov/teamstepps-program/curriculum/communication/tools/teachback.html)

- [Open RN](https://www.ncbi.nlm.nih.gov/books/NBK595001/table/ch10analgesics.T.ibuprofen_medication_gr/)

- [NICE](https://www.nice.org.uk/guidance/NG226/chapter/recommendations)

- [COX-2 primary paper](https://pmc.ncbi.nlm.nih.gov/articles/PMC4276492/)

- [Publisher abstract](https://www.sciencedirect.com/science/article/pii/S1047847714002433)

- [Human bioinversion](https://pubmed.ncbi.nlm.nih.gov/7937520/)

- [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/3672)

- [Pathway review](https://pmc.ncbi.nlm.nih.gov/articles/PMC4355401/)

- [PRECISION primary trial](https://pubmed.ncbi.nlm.nih.gov/27959716/)

## Patient

**Audience questions:** Why was it suggested? Why this pain reliever? How does it work? When might relief, another dose or a warning sign occur?

**Story order:** Conditional purpose and uses → choice and suitability → swallowing/absorption → simple COX mechanism → timing/wearing off → product and age/weight factors → explicitly scoped US OTC example → follow-up → possible mild effects → urgent signs.

**Research read:** NHS adult guidance; MedlinePlus drug information and child dosing; exact US OTC 200 mg label; prescription PK label; BCEHS onset.

**Evidence limits:** No personal prescribing inference, universal superiority, adult weight scaling, fixed benefit duration or side-effect resolution promise. UK comparison advice and US numeric label example are explicitly separated.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Caregiver

**Audience questions:** Which product was intended? How do we avoid duplicate doses? What should I observe and report?

**Story order:** Confirm purpose → product/strength/measurement → mechanism → observe response and keep a dose record → warning signs.

**Research read:** MedlinePlus drug information and child dosing; NHS; BCEHS.

**Evidence limits:** Adult tablet animation is not pediatric dosing. Weight and liquid concentration matter for children; do not improvise an adult-tablet conversion.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Pharmacist

**Audience questions:** How do formulation, exposure, interactions and product instructions change counseling?

**Story order:** Indication → reversible inhibition → dissolution/absorption and peak versus onset → reconciliation and aspirin interaction → counseling.

**Research read:** DailyMed prescription PK/pharmacodynamics and OTC directions; FDA aspirin interaction information.

**Evidence limits:** Aspirin interaction findings depend on regimen and formulation; no universal spacing rule. Peak concentration is not permission to redose.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Clinician

**Audience questions:** What symptom/function is the goal, and what evidence determines continued suitability?

**Story order:** Indication and risk → rationale → systemic exposure → assess pain/function and underlying cause → individualized risk and review.

**Research read:** DailyMed prescribing information; NICE NG226 osteoarthritis guidance located; NHS.

**Evidence limits:** NICE context is osteoarthritis, not every pain indication. Source web access to NICE was blocked; its indexed recommendations were read, and the script makes no new NICE-specific regimen claim.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Nurse

**Audience questions:** What must be checked before administration? What response and warning signs need assessment?

**Story order:** Confirm order/product and baseline → action → reassess → document/escalate → teach-back.

**Research read:** Open RN Nursing Pharmacology, Table 10.6c indexed complete medication grid; AHRQ Teach-Back page; official labeling.

**Evidence limits:** Follow local care plan for monitoring; no blanket laboratory schedule. Teach-back supports checking understanding, not a guarantee of comprehension.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Student

**Audience questions:** How does an oral product connect to a target, useful effects and protective pathway tradeoffs?

**Story order:** Purpose → release/dissolution/absorption/distribution → reversible COX inhibition → response/timing → protective functions and risk.

**Research read:** Open RN mechanism chapter and medication grid; DailyMed PK; PharmGKB pathway review; BCEHS.

**Evidence limits:** Separate movement in a teaching animation from measured concentrations, kinetics or clinical time. No fixed target occupancy or tissue-selectivity claim.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Scientist

**Audience questions:** Which isoforms and experimental conditions? What establishes binding versus inhibition versus human benefit?

**Story order:** Outcome → COX pathway → murine structural evidence → assay/substrate context → exposure gap → proposed controlled readouts → human evidence.

**Research read:** Primary COX-2 crystallography paper, PMC4276492 and publisher abstract; PharmGKB pathway review; DailyMed PK.

**Evidence limits:** Read available indexed primary-paper methods/abstract because direct full-text requests were challenged. Species, assay and structure-to-human inference are explicit; proposed experiments are not results.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Chemist

**Audience questions:** What do identity, chirality, formulation and binding actually establish?

**Story order:** Chemical question → connectivity/stereocenter → human bioinversion → structural context → matched analog comparisons → dissolution/exposure → clinical limits.

**Research read:** PubChem CID 3672 indexed record; primary human bioinversion study PMID 7937520; primary COX-2 structure paper; DailyMed solubility.

**Evidence limits:** Dynamic PubChem and direct PubMed full text were unavailable; indexed records/abstracts support bounded claims. No invented analog potency series or clinical advantage of a stereoisomer.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## Investor / Diligence Analyst

**Audience questions:** Which evidence link supports a proposed improvement, and what comparator would establish value?

**Story order:** Clinical need → molecular-to-human evidence chain → formulation/exposure gap → comparator/outcomes → absolute event counts and uncertainty.

**Research read:** PRECISION randomized trial primary abstract (PMID 27959716; NEJM DOI 10.1056/NEJMoa1611593) located and indexed methods read; official labels and COX-2 paper.

**Evidence limits:** Trial enrolled arthritis patients with elevated cardiovascular risk; no universal safety ranking, commercial differentiation, forecast or valuation inferred. Full publisher/PDF retrieval blocked; no new trial effect-size claim used.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.

## General

**Audience questions:** What is this medicine for and how does a tablet affect the body?

**Story order:** Common uses → route and clearance → basic action → variable onset → practical label and duplicate-product checks.

**Research read:** MedlinePlus drug information; NHS; DailyMed PK; BCEHS.

**Evidence limits:** A general explanation is distinct from the longer Patient decision/time-course story; neither diagnoses the cause or sets a personal dose.

**Implementation:** Expanded the role-specific narration in all three languages. Each sentence shares its section visual/source; captions remain above the model. Source/visual mappings and full wording follow in the script review. Existing video selection is retained; specialist/language gaps remain explicit.